Gecko is focused on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases.
The deal will see Teva acquire Gecko Health Innovations’ new cloud-based solution CareTRx, which is designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools.
Teva will now explore new ways to apply the CareTRx technology to its pipeline and portfolio of respiratory products in order to improve clinical outcomes for patients.
Commenting on the deal, Teva Global Specialty Medicines president and CEO Rob Koremans said: “The acquisition of Gecko Health Innovations further enhances Teva’s ability to develop and deliver truly patient-centred solutions by utilising eConnected, data-driven technology to improve the management of respiratory diseases.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Teva chief scientific officer and Global R&D president Michael Hayden said: “Teva is committed to optimising respiratory care through the development of new therapies and novel delivery systems to better serve patients living with respiratory conditions.”
CareTRx includes a hardware device, which attaches to most metered-dose inhalers (MDIs), as well as a software programme to synchronise and store data through an app-based user interface.
The new eConnected respiratory disease management platform strengthens Teva’s respiratory technology development capabilities.
This July, Teva agreed to acquire Allergan‘s generic drug unit Allergan Generics for around $40.5bn.
The acquired business is expected to transform Teva’s global generics space through expanding its generics pipeline, R&D capabilities, operational network, supply chain, global commercial deployment and infrastructure.
The deal will see Teva pay $33.75bn in cash and provide $6.75bn worth shares to Allergan, representing an estimated under 10% ownership stake in Teva.
Image: The acquisition of Gecko Health Innovations will strengthen Teva’s respiratory drug portfolio. Photo: courtesy of Piyachok Thawornmat/FreeDigitalPhotos.net.